This fact may be also one of the reasons that CML-T1 cells, where survivin is localized correctly after DAC + SAHA treatment, are resistant to ATRA addition to epigenetic drugs combination. Here, BIRC5 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.